AML, Adult
5
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Qihan BiotechChina - Hangzhou
4 programs4
CD33/CLL1 dual CAR-NK cellPhase 11 trial
QN-023aPhase 11 trial
QN-023aPhase 11 trial
QN-030aPhase 11 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qihan BiotechCD33/CLL1 dual CAR-NK cell
Qihan BiotechQN-030a
Qihan BiotechQN-023a
Qihan BiotechQN-023a
FUJIFILM PharmaFF-10101-01
Chipscreen Bioscienceschidamide and azacitidine
Clinical Trials (6)
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Start: Jul 2023Est. completion: Jan 2025
Phase 1Completed
Natural Killer(NK) Cell Therapy in r/r AML
Start: Dec 2022Est. completion: Dec 2025
Phase 1Unknown
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Start: Dec 2022Est. completion: Dec 2025
Phase 1Unknown
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Start: Mar 2022Est. completion: Apr 2023
Phase 1Terminated
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Start: May 2017Est. completion: Jul 2021
Phase 1Completed
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Start: Oct 2023Est. completion: Dec 2026
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
4 companies competing in this space